List view / Grid view
A new study has provided insights into how a novel tuberculosis vaccine strategy could work by speeding up the T cell responses in the lungs to shut down infection rapidly.
Dr Owen Seddon, University Hospital of Wales, looks at how lessons learned during the pandemic can inform pre-clinical and early R&D phases of future vaccine work.
In a new study, researchers have demonstrated the efficiency of T-cell immune response against the Omicron variant of SARS-CoV-2.
Researchers have found new ways to artificially induce mRNA to respond in ways that could eventually lead to therapeutic outcomes.
The antigen-based vaccine has the potential to induce sterilising immunity to old and new SARS-CoV-2 variants by preventing infection by stopping viral replication and transmission through the inhibition of cellular virus entry.
Pfizer has announced its acquisition of ReViral to advance disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus infections and prevent illness through vaccination.
Pre-clinical research from VBI Vaccines has demonstrated an encouraging ability to boost and broaden the immune response against the coronavirus Beta variant.
The COVID-19 pandemic has placed a spotlight on the discovery and development of biotherapeutics, for both the treatment and prevention of diseases. In this article, industry experts discuss the emerging trends they see in biotherapeutic development and how they predict the field will evolve in the near future.
Messenger RNA (mRNA) may be the ‘skeleton key’ that unlocks the door to fight latent viral infections that have plagued researchers for generations. Dr Sandeep Basnet, Director, Clinical Development at Moderna Therapeutics explores modern vaccine development and why mRNA is taking centre stage.
Dr John Lewis, CEO of Entos Pharmaceuticals, outlines how an innovative proteolipid platform could enable a new class of DNA-based vaccines in this article.
Protecting against conditions that appear in older generations is increasingly becoming a focus of the medical industry. In this article, Dr Andrea Pfeifer, CEO and Director of AC Immune, discusses the current landscape of vaccine development for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
This ebook includes articles about antibody-based therapies that could protect against cancer by utilising a patient's memory B cells. Also included is a piece on an intranasally-delivered monoclonal antibody treatment to potentially protect against SARS-CoV-2.
Scientists at Northwestern Medicine have developed new techniques in human blood to pave potential paths towards a HIV cure.
In this ebook, find articles on vaccination strategies for neurodegenerative diseases and the benefits of mRNA vaccine platforms against latent viruses.
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
